Compare Royal Bank of Canada (RY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs TG Therapeutics Inc — how do they compare? Royal Bank of Canada trades at $213.42 (market cap $292.32B), while TG Therapeutics Inc trades at $49.56 (market cap $7.64B). The key difference: Royal Bank of Canada is far larger — about 38.3× TG Therapeutics Inc's market cap, and Royal Bank of Canada pays a 2.37% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RY | TGTX | |
|---|---|---|
Market Cap | $292.32B | $7.64B |
Sector | Financials | Health |
52-Week High | $217.87 | $59.06 |
52-Week Low | $134.80 | $26.94 |
Dividend Yield | 2.37% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $212.67, up 0.89% today, with a bullish technical signal and recent quarterly earnings beats. The stock shows strong fundamentals with 2025 revenue of $66.53B and net income of $20.36B, yielding a 31.85% net margin. Analyst consensus is mixed with 43% buy ratings, while recent news highlights insider selling and dividend declarations.
RY presents a solid investment case with robust profitability and dividend appeal, but risks include high valuation multiples and mixed institutional sentiment. Upside is supported by earnings momentum, though macroeconomic and competitive pressures warrant caution for near-term performance.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
